Quince Therapeutics (QNCX) Competitors $1.61 +0.01 (+0.63%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.61 0.00 (0.00%) As of 01/31/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QNCX vs. TRVI, DSGN, AVIR, AQST, RZLT, IMMP, CCCC, VYGR, YMAB, and MBIOShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Trevi Therapeutics (TRVI), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Aquestive Therapeutics (AQST), Rezolute (RZLT), Immutep (IMMP), C4 Therapeutics (CCCC), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Trevi Therapeutics Design Therapeutics Atea Pharmaceuticals Aquestive Therapeutics Rezolute Immutep C4 Therapeutics Voyager Therapeutics Y-mAbs Therapeutics Mustang Bio Quince Therapeutics (NASDAQ:QNCX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Which has higher valuation and earnings, QNCX or TRVI? Trevi Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.30Trevi TherapeuticsN/AN/A-$29.07M-$0.44-8.95 Does the media prefer QNCX or TRVI? In the previous week, Trevi Therapeutics had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 7 mentions for Trevi Therapeutics and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.06 beat Trevi Therapeutics' score of 0.43 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor QNCX or TRVI? Trevi Therapeutics received 89 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 65.52% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesTrevi TherapeuticsOutperform Votes9565.52% Underperform Votes5034.48% Do institutionals & insiders believe in QNCX or TRVI? 30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 24.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is QNCX or TRVI more profitable? Quince Therapeutics' return on equity of -53.27% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Trevi Therapeutics N/A -63.31%-57.06% Do analysts prefer QNCX or TRVI? Quince Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 490.06%. Trevi Therapeutics has a consensus price target of $9.31, suggesting a potential upside of 136.36%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Trevi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has more volatility & risk, QNCX or TRVI? Quince Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. SummaryTrevi Therapeutics beats Quince Therapeutics on 8 of the 15 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.16M$3.06B$5.59B$9.12BDividend YieldN/A1.84%5.31%3.99%P/E Ratio-1.3016.2057.1113.81Price / SalesN/A317.891,261.0581.64Price / CashN/A190.0245.9637.70Price / Book0.814.125.124.71Net Income-$31.39M-$40.99M$111.17M$224.24M7 Day Performance1.26%-0.44%2.37%-0.17%1 Month Performance-13.90%0.93%3.19%0.60%1 Year Performance22.90%-1.69%24.69%20.43% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.8053 of 5 stars$1.61+0.6%$9.50+490.1%+29.8%$72.16MN/A-1.3060News CoveragePositive NewsTRVITrevi Therapeutics2.5838 of 5 stars$3.76-0.5%$9.31+147.7%+177.5%$289.03MN/A-8.5520Short Interest ↓News CoverageDSGNDesign Therapeutics2.1546 of 5 stars$5.06+6.8%$7.00+38.3%+104.6%$286.50MN/A-5.9540Short Interest ↑News CoverageGap DownAVIRAtea Pharmaceuticals3.5123 of 5 stars$3.37+1.2%$6.88+104.2%-26.4%$284.63MN/A-1.6370Short Interest ↓News CoverageAQSTAquestive Therapeutics1.4157 of 5 stars$3.10+0.3%$11.00+254.8%+26.4%$282.66M$50.58M-6.89160Short Interest ↑RZLTRezolute3.2285 of 5 stars$4.87+2.3%$24.13+395.4%+377.3%$282.17MN/A-3.8340IMMPImmutep1.8904 of 5 stars$1.93-0.5%$8.50+340.4%-3.7%$280.93M$5.14M0.002,021News CoverageCCCCC4 Therapeutics2.1143 of 5 stars$3.94+2.1%$10.67+170.7%-43.9%$278.13M$20.76M-2.32150Positive NewsVYGRVoyager Therapeutics4.7456 of 5 stars$5.07+0.2%$15.97+214.9%-25.0%$276.97M$250.01M7.14100YMABY-mAbs Therapeutics2.1259 of 5 stars$6.16-0.3%$20.89+239.1%-53.3%$275.91M$84.82M-11.41150MBIOMustang Bio2.9789 of 5 stars$5.55-5.6%$100.00+1,701.8%-94.0%$265.18MN/A-3.56100Short Interest ↓ Related Companies and Tools Related Companies Trevi Therapeutics Alternatives Design Therapeutics Alternatives Atea Pharmaceuticals Alternatives Aquestive Therapeutics Alternatives Rezolute Alternatives Immutep Alternatives C4 Therapeutics Alternatives Voyager Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Mustang Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNCX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
